Neuropace, Inc.

Good afternoon, and welcome to NeuroPay's second quarter earnings conference call. At this time, all participants are on the listen-only mode. We will be facilitating question and answer sessions towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to send the call over to Matt Baxo from the Gilmour & Group for a few introductory comments. Please go ahead.

Thank you, Operator. Good afternoon, and thank you for participating in today's call.

Joining me from NeuroPace are Mike Favitt, CEO, and Rebecca Kuhn, CFO. Earlier today, NeuroPace released financial results for the second quarter ended June 30, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including those around NeuroPACE's business development opportunities or projections, market conditions, clinical trials, and those relating to our operating trends and future financial performance, the impact of COVID-19 on our business and prospects for recovery, expense management, market opportunity, revenue outlook, and commercial expansion, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that cause actual results or events to materially differ from those implied by these forward-looking statements. Accordingly, you should not place under-reliance on these statements. For more detailed description of the risks and uncertainties associated with our business, please refer to the risk factors section of our public filings with the Securities and Exchange Commission, or SEC, including our annual report on Form 10-K for the year ended December 31st, 2021, filed with the SEC on March 10th, 2022, and our quarterly report on form 10Q to be filed with the SEC on August 11th, 2022, as well as any reports that we may file with the SEC in the future. This conference call contains time-sensitive information, which we believe is accurate only as of the live broadcast on August 11, 2022. NeuroPace disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Mike.